HIV combo therapy suppresses HBV in some patients

04/29/2013 | MedPage Today (free registration)

Tenofovir and emtricitabine can suppress hepatitis B among patients in the immune-tolerant stage, according to a study presented at a liver disease research meeting in Europe. Researchers tracked 126 HBV patients and found that 76% of those who took the tenofovir-emtricitabine combination for four years experienced viral suppression compared with 55% of those who received tenofovir alone. Few patients, however, regained their immune response to the pathogen, and among participants who stopped taking the drugs, viral loads returned to pre-study levels.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Confidential
Pompano Beach, FL